Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an announcement.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, develops therapies for gout and progressive kidney disease, including advanced programs XRx-026, XRx-008 and XRx-101, plus a pre-clinical candidate for Type 2 diabetic nephropathy. The firm’s drugs target purine metabolism and xanthine oxidase to lower uric acid and address serious renal and metabolic disorders.
The company reported that independent proxy advisory firms, including Institutional Shareholder Services, have recommended shareholders vote in favor of a proposed share consolidation at its March 24, 2026 meeting. The endorsement is seen as supporting XORTX’s view that consolidation could broaden financing alternatives and bolster long-term growth prospects, and the board is urging eligible shareholders of record to vote for all resolutions ahead of the March 20 proxy deadline.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced drug candidates: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and organ injury linked to respiratory virus infections, alongside pre-clinical program XRx-225 for Type 2 diabetic nephropathy.
The company’s approach targets aberrant purine metabolism and xanthine oxidase to reduce uric acid production, aiming to improve quality of life for patients with gout and other serious renal and metabolic conditions. XORTX is listed on Nasdaq, the TSX Venture Exchange and the Frankfurt exchange, positioning it to access both North American and European capital markets.
Average Trading Volume: 7,343
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
For a thorough assessment of XRTX stock, go to TipRanks’ Stock Analysis page.